These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36937127)

  • 1. Aldosterone Synthase Inhibitors and Dietary Interventions: A Combined Novel Approach for Prevention and Treatment of Cardiovascular Disease.
    Awosika A; Khan A; Adabanya U; Omole AE; Millis RM
    Cureus; 2023 Mar; 15(3):e36184. PubMed ID: 36937127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Hypertens Res; 2023 Jan; 46(1):108-118. PubMed ID: 36266539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salt-sensitive hypertension resulting from nitric oxide synthase inhibition is associated with loss of regulation of angiotensin II in the rat.
    Hodge G; Ye VZ; Duggan KA
    Exp Physiol; 2002 Jan; 87(1):1-8. PubMed ID: 11805851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race, obesity, and the renin-angiotensin-aldosterone system: treatment response in children with primary hypertension.
    South AM; Arguelles L; Finer G; Langman CB
    Pediatr Nephrol; 2017 Sep; 32(9):1585-1594. PubMed ID: 28411317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
    Bavishi C; Bangalore S; Messerli FH
    Prog Cardiovasc Dis; 2016; 59(3):253-261. PubMed ID: 27777044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone synthase inhibitors in hypertension: current status and future possibilities.
    Hargovan M; Ferro A
    JRSM Cardiovasc Dis; 2014 Jan; 3():2048004014522440. PubMed ID: 24570839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Therapies for Treatment-Resistant Hypertension: A Review of Lorundrostat and Related Selective Aldosterone Synthase Inhibitors.
    Feldman JM; Frishman WH; Aronow WS
    Cardiol Rev; 2024 Feb; ():. PubMed ID: 38358268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.
    Unger T; Paulis L; Sica DA
    Eur Heart J; 2011 Nov; 32(22):2739-47. PubMed ID: 21951628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension.
    Dey S; Frishman WH; Aronow WS
    Cardiol Rev; 2023 Aug; ():. PubMed ID: 37548462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.
    Loader J; Taylor FC; Lampa E; Sundström J
    J Am Heart Assoc; 2022 Jun; 11(11):e025289. PubMed ID: 35624081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmodulation as the mechanism for salt sensitivity of blood pressure in individuals with hypertension and type 2 diabetes mellitus.
    Underwood PC; Chamarthi B; Williams JS; Vaidya A; Garg R; Adler GK; Grotzke MP; Staskus G; Wadwekar D; Hopkins PN; Ferri C; McCall A; McClain D; Williams GH
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3775-82. PubMed ID: 22865897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
    Browne GA; Griffin TP; O'Shea PM; Dennedy MC
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase.
    Makhanova N; Hagaman J; Kim HS; Smithies O
    Hypertension; 2008 Jan; 51(1):134-40. PubMed ID: 18039983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary salt modifies the blood pressure response to renin-angiotensin inhibition in experimental chronic kidney disease.
    Bovée DM; Uijl E; Severs D; Rubio-Beltrán E; van Veghel R; Maassen van den Brink A; Joles JA; Zietse R; Cuevas CA; Danser AHJ; Hoorn EJ
    Am J Physiol Renal Physiol; 2021 Apr; 320(4):F654-F668. PubMed ID: 33586496
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.